Loading…
Metformin in non-alcoholic steatohepatitis
There is no established treatment for steatohepatitis in patients who are not alcoholics. This disease is a potentially progressive liver disease associated with hepatic insulin resistance. Only a weight-reducing diet in overweight patients has proved effective. We treated 20 patients who had steato...
Saved in:
| Published in: | The Lancet (British edition) 2001-09, Vol.358 (9285), p.893-894 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c497t-79ed767d334c3c95d51d43e2612bbb693a5da50f5b782c34c9d7cc3c52b56863 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c497t-79ed767d334c3c95d51d43e2612bbb693a5da50f5b782c34c9d7cc3c52b56863 |
| container_end_page | 894 |
| container_issue | 9285 |
| container_start_page | 893 |
| container_title | The Lancet (British edition) |
| container_volume | 358 |
| creator | Marchesini, Giulio Bianchi, Giampaolo Tomassetti, Sara Zoli, Marco Melchionda, Nazario |
| description | There is no established treatment for steatohepatitis in patients who are not alcoholics. This disease is a potentially progressive liver disease associated with hepatic insulin resistance. Only a weight-reducing diet in overweight patients has proved effective. We treated 20 patients who had steatohepatitis but were not alcoholics with metformin (500 mg three times a day for 4 months), an agent that improves hepatic insulin sensitivity. When compared with the six individuals not complying with treatment, long-term metformin significantly reduced mean transaminase concentrations, which returned to normal in 50% of actively-treated patients. Also, insulin sensitivity improved significantly and liver volume decreased by 20%. Similar data have been reported in insulin-resistant ob/ob mice with fatty liver. A randomised-controlled study is needed. |
| doi_str_mv | 10.1016/S0140-6736(01)06042-1 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71193218</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673601060421</els_id><sourcerecordid>2068341446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-79ed767d334c3c95d51d43e2612bbb693a5da50f5b782c34c9d7cc3c52b56863</originalsourceid><addsrcrecordid>eNqF0E1LJDEQBuAgLjp-_ARFVGQVWqs6X5OTiLi7guLBOXgL6SSNkZ7OmPQI---3e2bQRRAhUJen3hQvIXsI5wgoLh4BGRRCUvET8BQEsLLANTJCJlnBmXxaJ6N3skm2cn4BACaAb5BNRC6kRBiRs3vf1TFNQ3vQvza2hWlsfI5NsAe586aLz35mutCFvEN-1KbJfnc1t8nk183k-k9x9_D79vrqrrBMya6QyjsppKOUWWoVdxwdo74UWFZVJRQ13BkONa_kuLQ9Uk7aXvKy4mIs6DY5WcbOUnyd-9zpacjWN41pfZxnLREVLXHcw6NP8CXOU9ufpksQY8qQsSHu8CuFSgEHzoYovkQ2xZyTr_UshalJfzWCHurWi7r10KUG1Iu6NfZ7-6vweTX17mNr1W8PjlfAZGuaOpnWhvyfK5Xiw_-XS-b7Xt-CTzrb4FvrXUjedtrF8M0l_wBixpjq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199050548</pqid></control><display><type>article</type><title>Metformin in non-alcoholic steatohepatitis</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><source>Business Source Ultimate (EBSCOHost)</source><creator>Marchesini, Giulio ; Bianchi, Giampaolo ; Tomassetti, Sara ; Zoli, Marco ; Melchionda, Nazario</creator><creatorcontrib>Marchesini, Giulio ; Bianchi, Giampaolo ; Tomassetti, Sara ; Zoli, Marco ; Melchionda, Nazario</creatorcontrib><description>There is no established treatment for steatohepatitis in patients who are not alcoholics. This disease is a potentially progressive liver disease associated with hepatic insulin resistance. Only a weight-reducing diet in overweight patients has proved effective. We treated 20 patients who had steatohepatitis but were not alcoholics with metformin (500 mg three times a day for 4 months), an agent that improves hepatic insulin sensitivity. When compared with the six individuals not complying with treatment, long-term metformin significantly reduced mean transaminase concentrations, which returned to normal in 50% of actively-treated patients. Also, insulin sensitivity improved significantly and liver volume decreased by 20%. Similar data have been reported in insulin-resistant ob/ob mice with fatty liver. A randomised-controlled study is needed.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(01)06042-1</identifier><identifier>PMID: 11567710</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Adult ; Alanine Transaminase - metabolism ; Alcoholics ; Animal models ; Biological and medical sciences ; Biopsy ; Body Mass Index ; Body weight ; Body Weight - drug effects ; Diabetes ; Digestive system ; Drug dosages ; Drug therapy ; Fatty liver ; Fatty Liver - diet therapy ; Fatty Liver - drug therapy ; Fatty Liver - enzymology ; Female ; Glucose ; Hepatitis ; Humans ; Hypoglycemic Agents - therapeutic use ; Insulin ; Insulin resistance ; Liver ; Liver diseases ; Male ; Medical research ; Medical sciences ; Metformin ; Metformin - therapeutic use ; Middle Aged ; Obesity ; Overweight ; Patients ; Pharmacology. Drug treatments ; Sensitivity ; Transaminase ; Treatment Outcome ; Ultrasonic imaging ; Weight control ; Weight reduction</subject><ispartof>The Lancet (British edition), 2001-09, Vol.358 (9285), p.893-894</ispartof><rights>2001 Elsevier Ltd</rights><rights>2001 INIST-CNRS</rights><rights>Copyright Lancet Ltd. Sep 15, 2001</rights><rights>Copyright Elsevier Limited Sep 15, 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-79ed767d334c3c95d51d43e2612bbb693a5da50f5b782c34c9d7cc3c52b56863</citedby><cites>FETCH-LOGICAL-c497t-79ed767d334c3c95d51d43e2612bbb693a5da50f5b782c34c9d7cc3c52b56863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1129958$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11567710$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marchesini, Giulio</creatorcontrib><creatorcontrib>Bianchi, Giampaolo</creatorcontrib><creatorcontrib>Tomassetti, Sara</creatorcontrib><creatorcontrib>Zoli, Marco</creatorcontrib><creatorcontrib>Melchionda, Nazario</creatorcontrib><title>Metformin in non-alcoholic steatohepatitis</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>There is no established treatment for steatohepatitis in patients who are not alcoholics. This disease is a potentially progressive liver disease associated with hepatic insulin resistance. Only a weight-reducing diet in overweight patients has proved effective. We treated 20 patients who had steatohepatitis but were not alcoholics with metformin (500 mg three times a day for 4 months), an agent that improves hepatic insulin sensitivity. When compared with the six individuals not complying with treatment, long-term metformin significantly reduced mean transaminase concentrations, which returned to normal in 50% of actively-treated patients. Also, insulin sensitivity improved significantly and liver volume decreased by 20%. Similar data have been reported in insulin-resistant ob/ob mice with fatty liver. A randomised-controlled study is needed.</description><subject>Adult</subject><subject>Alanine Transaminase - metabolism</subject><subject>Alcoholics</subject><subject>Animal models</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Body Mass Index</subject><subject>Body weight</subject><subject>Body Weight - drug effects</subject><subject>Diabetes</subject><subject>Digestive system</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Fatty liver</subject><subject>Fatty Liver - diet therapy</subject><subject>Fatty Liver - drug therapy</subject><subject>Fatty Liver - enzymology</subject><subject>Female</subject><subject>Glucose</subject><subject>Hepatitis</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Metformin</subject><subject>Metformin - therapeutic use</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Overweight</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Sensitivity</subject><subject>Transaminase</subject><subject>Treatment Outcome</subject><subject>Ultrasonic imaging</subject><subject>Weight control</subject><subject>Weight reduction</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNqF0E1LJDEQBuAgLjp-_ARFVGQVWqs6X5OTiLi7guLBOXgL6SSNkZ7OmPQI---3e2bQRRAhUJen3hQvIXsI5wgoLh4BGRRCUvET8BQEsLLANTJCJlnBmXxaJ6N3skm2cn4BACaAb5BNRC6kRBiRs3vf1TFNQ3vQvza2hWlsfI5NsAe586aLz35mutCFvEN-1KbJfnc1t8nk183k-k9x9_D79vrqrrBMya6QyjsppKOUWWoVdxwdo74UWFZVJRQ13BkONa_kuLQ9Uk7aXvKy4mIs6DY5WcbOUnyd-9zpacjWN41pfZxnLREVLXHcw6NP8CXOU9ufpksQY8qQsSHu8CuFSgEHzoYovkQ2xZyTr_UshalJfzWCHurWi7r10KUG1Iu6NfZ7-6vweTX17mNr1W8PjlfAZGuaOpnWhvyfK5Xiw_-XS-b7Xt-CTzrb4FvrXUjedtrF8M0l_wBixpjq</recordid><startdate>20010915</startdate><enddate>20010915</enddate><creator>Marchesini, Giulio</creator><creator>Bianchi, Giampaolo</creator><creator>Tomassetti, Sara</creator><creator>Zoli, Marco</creator><creator>Melchionda, Nazario</creator><general>Elsevier Ltd</general><general>Lancet</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20010915</creationdate><title>Metformin in non-alcoholic steatohepatitis</title><author>Marchesini, Giulio ; Bianchi, Giampaolo ; Tomassetti, Sara ; Zoli, Marco ; Melchionda, Nazario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-79ed767d334c3c95d51d43e2612bbb693a5da50f5b782c34c9d7cc3c52b56863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Alanine Transaminase - metabolism</topic><topic>Alcoholics</topic><topic>Animal models</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Body Mass Index</topic><topic>Body weight</topic><topic>Body Weight - drug effects</topic><topic>Diabetes</topic><topic>Digestive system</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Fatty liver</topic><topic>Fatty Liver - diet therapy</topic><topic>Fatty Liver - drug therapy</topic><topic>Fatty Liver - enzymology</topic><topic>Female</topic><topic>Glucose</topic><topic>Hepatitis</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Metformin</topic><topic>Metformin - therapeutic use</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Overweight</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Sensitivity</topic><topic>Transaminase</topic><topic>Treatment Outcome</topic><topic>Ultrasonic imaging</topic><topic>Weight control</topic><topic>Weight reduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marchesini, Giulio</creatorcontrib><creatorcontrib>Bianchi, Giampaolo</creatorcontrib><creatorcontrib>Tomassetti, Sara</creatorcontrib><creatorcontrib>Zoli, Marco</creatorcontrib><creatorcontrib>Melchionda, Nazario</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marchesini, Giulio</au><au>Bianchi, Giampaolo</au><au>Tomassetti, Sara</au><au>Zoli, Marco</au><au>Melchionda, Nazario</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metformin in non-alcoholic steatohepatitis</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2001-09-15</date><risdate>2001</risdate><volume>358</volume><issue>9285</issue><spage>893</spage><epage>894</epage><pages>893-894</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>There is no established treatment for steatohepatitis in patients who are not alcoholics. This disease is a potentially progressive liver disease associated with hepatic insulin resistance. Only a weight-reducing diet in overweight patients has proved effective. We treated 20 patients who had steatohepatitis but were not alcoholics with metformin (500 mg three times a day for 4 months), an agent that improves hepatic insulin sensitivity. When compared with the six individuals not complying with treatment, long-term metformin significantly reduced mean transaminase concentrations, which returned to normal in 50% of actively-treated patients. Also, insulin sensitivity improved significantly and liver volume decreased by 20%. Similar data have been reported in insulin-resistant ob/ob mice with fatty liver. A randomised-controlled study is needed.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>11567710</pmid><doi>10.1016/S0140-6736(01)06042-1</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2001-09, Vol.358 (9285), p.893-894 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71193218 |
| source | Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list); Business Source Ultimate (EBSCOHost) |
| subjects | Adult Alanine Transaminase - metabolism Alcoholics Animal models Biological and medical sciences Biopsy Body Mass Index Body weight Body Weight - drug effects Diabetes Digestive system Drug dosages Drug therapy Fatty liver Fatty Liver - diet therapy Fatty Liver - drug therapy Fatty Liver - enzymology Female Glucose Hepatitis Humans Hypoglycemic Agents - therapeutic use Insulin Insulin resistance Liver Liver diseases Male Medical research Medical sciences Metformin Metformin - therapeutic use Middle Aged Obesity Overweight Patients Pharmacology. Drug treatments Sensitivity Transaminase Treatment Outcome Ultrasonic imaging Weight control Weight reduction |
| title | Metformin in non-alcoholic steatohepatitis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T10%3A26%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metformin%20in%20non-alcoholic%20steatohepatitis&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Marchesini,%20Giulio&rft.date=2001-09-15&rft.volume=358&rft.issue=9285&rft.spage=893&rft.epage=894&rft.pages=893-894&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(01)06042-1&rft_dat=%3Cproquest_cross%3E2068341446%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c497t-79ed767d334c3c95d51d43e2612bbb693a5da50f5b782c34c9d7cc3c52b56863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=199050548&rft_id=info:pmid/11567710&rfr_iscdi=true |